Thalia Therapeutics

Default features description for sign up page.

Regulatory news

Home

Media

AIM Rule 26

Open Sans

THALIA THERAPEUTICS INVESTOR CENTRE

Video Overview by Nigel Theobald, CEO of N4 Pharma

We would like to thank all of our shareholders and prospective investors for submitting their questions on our June 2024 corporate presentation - see the presentation slides here.

Nigel answers the following questions throughout the presentation:

Can you provide an “elevator pitch style” overview of N4 Pharma's current strategic focus and how your two patented nanoparticle delivery systems are positioned to address unmet needs in cancer treatments, gene therapy, and vaccines?

How does N4 Pharma differentiate itself from other biotech companies in the preclinical stage?

Can you explain how the Liptide® peptide/lipid delivery system works, especially in preventing fibrosis post-glaucoma surgery?

What makes the Nuvec® delivery system unique, and what are its key advantages over existing delivery systems?

How has the recent partnership with SRI International and other collaborations influenced N4 Pharma's market positioning and R&D capabilities?

What types of potential commercial and licensing opportunities do you foresee for Nuvec® and LipTide®?

What are the key valuation inflexion milestones for N4 Pharma in the next 12 months, and how do they align with your overall growth strategy?

With the strong market focus on RNA therapy delivery, how is N4 Pharma planning to leverage this trend to attract investment and strategic partnerships?

What can investors expect in terms of news flow and updates in the coming months?

Please watch the video below and submit any questions you may have, our team will always get back to you.

N4 Pharma - June 2024 Company Presentation Video